Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); SNY vs. FDA on m-enox: New Judge, Same Pro-FDA Sentiment
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $23.00.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on stabilized near-term m-enox revenue, generic Copaxone potential. We think the Amphastar preliminary injunction may apply to other enoxes and hold until mid-2013. We estimate MNTA’s m-enox will capture 55% of the enoxaparin market until then. We think the generic Copaxone suit will resolve in Momenta’s favor mid-2012."
"We believe new case judge still favorably inclined to FDA/ Sandoz. In last week’s summary judgement hearing requested by Sanofi, Judge Amy Jackson deferred to FDA expertise on statute interpretations of information categories FDA could request in an ANDA. Recall Sanofi argues FDA exceeded its authority when approving m-enox under the 505(j) ANDA path by requesting immunogenicity data, which Sanofi argues is clinical safety data requiring 505(b)(2) review."
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $15.61 yesterday.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on stabilized near-term m-enox revenue, generic Copaxone potential. We think the Amphastar preliminary injunction may apply to other enoxes and hold until mid-2013. We estimate MNTA’s m-enox will capture 55% of the enoxaparin market until then. We think the generic Copaxone suit will resolve in Momenta’s favor mid-2012."
"We believe new case judge still favorably inclined to FDA/ Sandoz. In last week’s summary judgement hearing requested by Sanofi, Judge Amy Jackson deferred to FDA expertise on statute interpretations of information categories FDA could request in an ANDA. Recall Sanofi argues FDA exceeded its authority when approving m-enox under the 505(j) ANDA path by requesting immunogenicity data, which Sanofi argues is clinical safety data requiring 505(b)(2) review."
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $15.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
- Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
